SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Andere talen Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Aandelen

2196

CNE100001M79

Vertraagde tijd Hong Kong S.E. Andere beurzen 04:54:29 21-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,08 ^HKD	-3,40%		-2,39%	-23,06%

15/05	Fosun Pharma Unit Fosun Health krijgt kapitaalinjectie van Foshan Chanxi City Investment	MT
15/05	China keurt klinische proeven voor medicijnen tegen borstkanker goed	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	15/05
China Approves Clinical Trials For Breast Cancer Drugs	15/05
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	10/05
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	09/05
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	07/05
Fosun Pharma's Q1 Profit Slumps 38%	30/04
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24/04
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18/04
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17/04
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15/04
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08/04
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03/04
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	31/03
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27/03
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26/03
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Aandelen

2196

CNE100001M79

Andere talen

Filters